XUND receives 6 million euros in Pre-Series-A

AI-supported healthcare solutions on course for growth. The successful Pre-Series A will contribute to expansion in Europe.

Vienna, March 5, 2025 - Vienna-based healthtech scale-up XUND has closed a €6 million Pre-Series A financing round. The round was led by Lead Ventures, with participation from J&T Ventures, as well as existing investors MassMutual Ventures, tba network and LANA Ventures.

This investment is a validation of our team's hard work. It enables us to accelerate our expansion in Europe and further develop data-driven, personalized healthcare.

Tamás Petrovics, CEO and Co-Founder XUND

With the new funding, XUND aims to accelerate its expansion in the core DACH and UK markets. The company develops MDR-certified software as a medical device (SaMD) that enables digital patient experiences from prevention to diagnosis.

Transforming Europe's healthcare market with AI

The demand for certified AI-supported healthcare solutions is growing steadily. XUND is positioning itself as a leading provider of digital infrastructure in the healthcare sector by facilitating the integration of AI into existing systems with its products.

The new investments will enable XUND:

• Further develop its MDR-certified solutions
• Accelerate expansion in DACH and the UK
• Drive forward the integration of RAVE, the in-house Large Language Model (LLM)

The company also plays a key role in the EU's InvestAI initiative, which provides 200 billion euros for AI-supported solutions to strengthen Europe's technological sovereignty.

XUND brings clarity to critical healthcare decisions. Its use for a digitalized patient journey not only improves care, but also makes healthcare more efficient.

Balázs Haszonics, Managing Partner at Lead Ventures

XUND was founded in Vienna in 2018 and develops AI-supported medical products that support patients and healthcare professionals as certified software solutions. The company is active in the core European markets of Germany, Austria, Switzerland and the UK.